Literature DB >> 32616296

Endovascular management of mycotic aortic aneurysms- A 20-year experience from a single UK centre.

S Puppala1, G A Cuthbert2, C Tingerides3, D A Russell2, S J McPherson3.   

Abstract

AIM: To present the authors' experience of endovascular treatment of confirmed and presumed (microbiology negative) mycotic aortic aneurysms (MAA).
MATERIALS AND METHODS: Patients undergoing endovascular aortic repair were identified retrospectively from 1998 using the radiology information system and an internally kept database until 2018. The primary aim was to assess the technical success and peri-operative morbidity and mortality. The secondary aim was to assess progression of infection, re-interventions, late mortality, and correlation to antibiotic duration pre- and post-procedure.
RESULTS: Thirty-four endovascular aortic procedures were performed for MAA, excluding aorto-enteric fistulas, inflammatory aneurysms, and infected grafts without a new aneurysm. Seventy-six percent of these were thoracic and 24% abdominal. The technical success was 100%. Additional procedures were undertaken in four patients with two requiring a further endovascular procedure. There were two inpatient aneurysm-related mortalities and no inpatient conversions to open repair. The 30-day re-admission and re-intervention rate was 0%. Blood cultures were positive in 45%. There were no secondary graft infections.
CONCLUSION: This is the largest European single-centre study. It supports endovascular management of MAA as a lower-risk alternative to open surgery with the majority of patients presenting acutely, later in life and requiring emergency management. Crown
Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32616296     DOI: 10.1016/j.crad.2020.05.019

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  1 in total

1.  Management of a Mycotic Aneurysm in a Patient with COVID-19: A Case Report.

Authors:  Muzammil H Syed; Mark Wheatcroft; Danny Marcuzzi; Hooman Hennessey; Mohammad Qadura
Journal:  Medicina (Kaunas)       Date:  2021-06-14       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.